[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-idiopathic-thrombocytopenic-purpura\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-idiopathic-thrombocytopenic-purpura":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":4,"maxAge":4,"enrollmentInfo":15,"targetDuration":18,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":24,"lastUpdatePostDateStruct":25,"startDateStruct":28,"completionDateStruct":30,"leadSponsor":32,"locationsCount":5},"100574282",false,"NCT06757257","Special Drug Use-results Survey for Long-term Use (Fostamatinib)","Inclusion Criteria:\n\n* Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.","ALL",{"count":16,"type":17},149,"ESTIMATED","18 Months","OBSERVATIONAL","The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.",[22],"Chronic Idiopathic Thrombocytopenic Purpura","RECRUITING","2024-12-26",{"date":26,"type":27},"2025-01-03","ACTUAL",{"date":29,"type":27},"2023-05-29",{"date":31,"type":17},"2028-09-30",{"name":33,"class":34},"Kissei Pharmaceutical Co., Ltd.","INDUSTRY",""]